Urgent Notice to All Conference Participants

It has been brought to our attention that EHS Housing has recently been cold calling our speakers offering accommodation for a named Fusion conference. Please note that we have no association with EHS Housing and they are acting on our behalf without our permission. We strongly advise that any calls from EHS Housing are ignored or ended immediately. If you are contacted by EHS Housing, please notify us immediately.

All Fusion registration fees are inclusive of accommodation (for three fixed nights) and reservations are handled internally, entirely by Fusion Conferences. If you have any questions concerning your accommodation, please contact Fusion Conferences directly via admin@fusion-conferences.com.

Home > Past Conferences > Cancer Metabolism and the Tumour Microenvironment Conference

The registration process for this conference has now closed.

Registration Deadlines

Talk Submission – expired

Poster Submission – expired

Early bird – expired

Last Chance – expired

Cancer Metabolism and the Tumour Microenvironment Conference

Importance of Inflammation and Stromal Cells

09 Nov 2016 - 12 Nov 2016

Paphos, Cyprus

Synopsis

Cancer cells recruit normal cells such as endothelial cells, immune cells, adipocytes and fibroblasts, to establish a reactive tumour microenvironment. Researchers are rapidly expanding our knowledge of how cancer and stromal cells communicate, via metabolic changes and inflammation, and establish a symbiotic relationship that supports malignant progression and suppresses anti-tumour immunity.

Throughout the Cancer Metabolism and the Tumour Microenvironment meeting there will be an emphasis placed not only on the mechanisms underlying the metabolic crosstalk established between cancer cells and stromal cells, but also on the impact of context-specific metabolism on cancer development and progression, and on how to therapeutically target these metabolic processes in cancer.

This Cancer Metabolism meeting will bring together diverse researchers from the fields of cancer metabolism and stromal cell biology, providing an opportunity to discuss recent developments and new areas of cross-fertilization between those fields.

The main topics will include:

  • Tumour microenvironment metabolic pathways and tumour progression
  • Metabolism of circulating tumour cells and cancer stem cells
  • Inflammation and cancer initiation
  • Immune microenvironment and tumour progression
  • Targeting metabolism for cancer therapy

Learning Objectives

This Cancer Metabolism conference will cover the major aspects of the metabolic transformation of cancer cells, such as in tumour-initiating cells and circulating tumour cells. The conference will also highlight the role of key stromal cell types, such as cancer-associated fibroblasts and cells of the immune system, emphasising novel therapeutic approaches.

Target Audience 

Researchers and clinicians from the following specialty fields will be expected to attend, such as: cancer biology, translational medicine, cell biology, vascular biology, immunology, inflammation, medicinal chemistry, drug discovery, biomarker discovery, tumour microenvironment, metabolism, cancer stem cells and circulating tumour cells, among other fields.

Confirmed Speakers

Prof. Dr. Michael Lisanti (University of Manchester)
CANCER METABOLISM AND TUMOR HETEROGENEITY: MITOCHONDRIA IN CANCER STEM CELLS ARE A THERAPEUTIC TARGET

Dr. Federica Sotgia (University of Manchester)
UNDERSTANDING THE ROLE OF TELOMERASE IN CANCER STEM CELLS

Dr. Ubaldo E. Martinez Outschoorn (Thomas Jefferson University Hospitals)
HUMAN METABOLIC ECOSYSTEMS

Prof. Lluis Fajas (UNIL)
CELL CYCLE REGULATORS ARE MAJOR FACTORS IN ADAPTING THE MATABOLIC RESPONSE TO

Dr. Jacques Pouyssegur (University of Nice)
TARGETING BIOENERGETICS AND NUTRIENT SENSING IN HYPOXIC TUMOURS

Prof. Adrian Harris (Oxford University)
INTRATUMOUR HETEROGENEITY OF THE HYPOXIA RESPONSE, ROLES IN INVASION,  METABOLISM, STEM CELL BIOLOGY AND DRUG RESPONSE

Prof. Pierre Sonveaux (Catholic University of Louvain)
POSITIONING AUTOPHAGY IN THE METABOLIC SYMBIOSIS BASED ON THE EXCHANGE OF LACTATE BETWEEN OXIDATIVE AND GLYCOLYTIC CANCER CELLS

Prof. Arne Östman (Karolinska Institute)
CAFS AND PERIVASCULAR CELLS; IMPACT ON PROGNOSIS AND RESPONSE TO TREATMENT

Prof. Isaac Witz (Tel Aviv University)
ASTROCYTES, BRAIN ENDOTHELIAL CELLS AND MICROGLIA RESPOND EQUALLY TO BRAIN-METASTASIZING MELANOMA CELLS AND TO STROKE

Dr. Myriam Fabre (Oncomatryx)
TARGETING TUMOR MICROENVIRONMENT TO TREAT INVASIVE TUMORS: OMTX705, A POWERFUL FAP-SPECIFIC ANTIBODY-DRUG CONJUGATE

Dr. Michelangelo Campanella (The Royal Veterinary College, London)
THE 18KDA PROTEIN TSPO INHIBITS MITOCHONDRIAL AUTOPHAGY AND UNDERPINS METABOLIC REPROGRAMMING OF BREAST CANCER CELLS

Dr. Balázs Győrffy (Semmelweis University)
LINKING TP53 MUTATION TO ENERGY METABOLISM AND INCREASED GLYCOLYSIS IN BREAST CANCER

Assist. Prof. Ana Urbano (University of Coimbra)
METABOLIC ALTERATIONS PRODUCED BY HEXAVALENT CHROMIUM: INSIGHTS INTO THE MOLECULAR MECHANISMS UNDERLYING ITS CARCINOGENICITY

Dr. Balamurugan Kuppusamy (NIH/NCI) 
THE CEBPD TRANSCRIPTION FACTOR, A MARKER OF GOOD PROGNOSIS IN BREAST CANCER, BECOMES A SIGNALING HUB FOR PROMOTION OF CANCER CELL STEMNESS BY HYPOXIA AND INTERLEUKIN-6

Mark Musters (Lead Pharma)
TARGETING TUMOUR METABOLISM BY INHIBITION OF NUCLEAR RECPTOR ERRα WITH SMALL MOLECULAR COMPOUNDS

Matthew Hirschey (Duke University)
ACTIVATING LIPID METABOLISM AS A CANCER THERAPY

 

Sponsors

Sponsors

Programme

THIS IS A PRELIMINARY PROGRAMME AND IS SUBJECT TO CHANGE.

WEDNESDAY 9TH NOVEMBER 2016

14:00 – 15:00

Registration & Reception

14:00 – 14:45

Group Welcome Lunch

CANCER METABOLISM 
Session Chair: Ubaldo E. Martinez-Outschoorn

14:45 – 15:00

Opening Comments

 

15:00 – 15:30

Michael Lisanti
University of Salford

CANCER METABOLISM AND TUMOR HETEROGENEITY: MITOCHONDRIA IN CANCER STEM CELLS ARE A THERAPEUTIC TARGET

15:30 – 16:00

Adrian Harris
Oxford University

INTRATUMOUR HETEROGENEITY OF THE HYPOXIA RESPONSE, ROLES IN INVASION,  METABOLISM, STEM CELL BIOLOGY AND DRUG RESPONSE

16:00 – 16:30

Arne Ostman
Karolinska Institute

CAFS AND PERIVASCULAR CELLS; IMPACT ON PROGNOSIS AND RESPONSE TO TREATMENT

16:30 – 17:00

Dr. Jacques Pouyssegur
University of Nice

TARGETING BIOENERGETICS AND NUTRIENT SENSING IN HYPOXIC TUMOURS

17:00 – 17:30

Refreshments

METABOLIC SYMBIOSIS AND REPROGRAMMING  
Session Chair: Jacques Pouyssegur

17:30 – 18:00

Ubaldo E. Martinez Outschoorn
Thomas Jefferson University Hospitals

HUMAN METABOLIC ECOSYSTEMS

18:00 – 18:30

Pierre Sonveaux
Catholic University of Louvain

POSITIONING AUTOPHAGY IN THE METABOLIC SYMBIOSIS BASED ON THE EXCHANGE OF LACTATE BETWEEN OXIDATIVE AND GLYCOLYTIC CANCER CELLS

18:30 – 19:00

Lluis Fajas
University of Lausanne

CELL CYCLE REGULATORS ARE MAJOR FACTORS IN ADAPTING THE METABOLIC RESPONSE TO CANCER

19:00 – 19:30

Isaac Witz
Tel Aviv University

ASTROCYTES, BRAIN ENDOTHELIAL CELLS AND MICROGLIA RESPOND EQUALLY TO BRAIN-METASTASIZING MELANOMA CELLS AND TO STROKE

19:30 – 20:00

PM Panel Discussion

20:00

Group Dinner

THURSDAY 10TH NOVEMBER 2016

07:00 – 08:30

Group Breakfast

METABOLISM, AUTOPHAGY AND THE TUMOR MICROENVIRONMENT
Session Chair: Mark Musters

08:30 – 09:00

Federica Sotgia
University of Salford

UNDERSTANDING THE ROLE OF TELOMERASE IN CANCER STEM CELLS

09:00 – 09:30

Michelangelo Campanella
The Royal Veterinary College, London

THE 18KDA PROTEIN TSPO INHIBITS MITOCHONDRIAL AUTOPHAGY AND UNDERPINS METABOLIC REPROGRAMMING OF BREAST CANCER CELLS

09:30 – 10:00

Myriam Fabre
Oncomatryx

TARGETING TUMOR MICROENVIRONMENT TO TREAT INVASIVE TUMORS: OMTX705, A POWERFUL FAP-SPECIFIC ANTIBODY-DRUG CONJUGATE

10:00 – 10:30

Refreshments

10:30 – 11:00

Balázs Győrffy
MTA TTK

LINKING TP53 MUTATION TO ENERGY METABOLISM AND INCREASED GLYCOLYSIS IN BREAST CANCER

11:00 – 11:30

Ana Urbano
University of Coimbra

METABOLIC ALTERATIONS PRODUCED BY HEXAVALENT CHROMIUM: INSIGHTS INTO THE MOLECULAR MECHANISMS UNDERLYING ITS CARCINOGENICITY

11:30 – 12:00

AM Panel Discussion

12:00 – 16:30

Group Lunch & Free Time

13:00 – 16:00

Group Activity: Paphos Tombs of the Kings – Mosaics – Aphrodite’s Rock

NEW PROMISING TARGETS AND STRATEGIES FOR CANCER THERAPY
Session Chair: Balázs Győrffy

16:30 – 17:00

Mark Musters
Lead Pharma Medicine BV

TARGETING TUMOUR METABOLISM BY INHIBITION OF NUCLEAR RECPTOR ERRα WITH SMALL MOLECULAR COMPOUNDS

17:00 – 17:30

Balamurugan Kuppusamy
National Cancer Institute/National Institutes of Health

THE CEBPD TRANSCRIPTION FACTOR, A MARKER OF GOOD PROGNOSIS IN BREAST CANCER, BECOMES A SIGNALING HUB FOR PROMOTION OF CANCER CELL STEMNESS BY HYPOXIA AND INTERLEUKIN-6

17:30 – 18:00

Matthew Hirschey
Duke University

ACTIVATING LIPID METABOLISM AS A CANCER THERAPY

18:00 – 18:30

Refreshments

18:30 – 19:00

Derek Radisky
Mayo Clinic Cancer Center

EPITHELIAL AND STROMAL ALTERATIONS THAT DRIVE BREAST CANCER PROGRESSION FROM BENIGN BREAST DISEASE

19:00 – 19:30

Paola Marignani
Dalhousie University

IS METABOLISM THE INTERCEPT BETWEEN TUMOUR MICROENVIRONMENT AND EPIGENETIC CHANGES THAT SUPPORT CANCER?

19:30 – 20:00

PM Panel Discussion

20:00

Group Dinner

FRIDAY 11TH NOVEMBER 2016

07:00 – 08:30

Group Breakfast

INFLAMMATION AND CANCER PROGRESSION
Session Chair: Mike Berridge

08:30 – 09:00

Petr Benes
St. Anne's University Hospital, Czech Republic

SUPPRESSION OF BREAST CANCER LUNG METASTASES BY INFLAMMATORY SIGNATURE TARGETED BY c-MYB

09:00 – 09:30

Adit Ben-Baruch
Tel Aviv University

INFLAMMATION-DRIVEN TUMOR-STROMA INTERACTIONS IN BREAST CANCER: REGULATION OF METABOLIC AND PRO-TUMORAL TRAITS OF MESENCHYMAL STEM CELLS

09:30 – 10:00

Si Chen
ErasmusMC Rotterdam

INFLAMMATORY NICHE SIGNALLING DRIVES GENOTOXIC STRESS IN HEMATOPOIETIC STEM CELLS AND PREDICTS LEUKEMIC EVOLUTION IN HUMAN LEUKEMIA PREDISPOSITION SYNDROMES

10:00 – 10:30

AM Panel Discussion

10:30 – 11:00

Refreshments

11:45 – 17:00

Group Lunch & Free Time

12:45 – 16:30

Group Activity: Wine Tasting at Chryssogoriatissa Monasteries – Agios Neophytos

MITOCHONDRIA IN CANCER PATHOGENESIS
Session Chair: Arne Ostman

17:00 – 17:30

Mike Berridge
Malaghan Institute of Medical Research

MITOCHONDRIAL TRANSFER FROM THE MICROENVIRONMENT FACILITATES GROWTH AND METASTASIS OF TUMOUR CELLS WITHOUT MITOCHONDRIAL DNA

17:30 – 18:00

Igal Madar
Mitoluminate Diagnostics

18F-FBNTP - A NOVEL BIOMARKER FOR DIFFERENTIAL IMAGING OF OXIDATIVE AND NON-OXIDATIVE MICROREGIONS IN BREAST TUMOR

18:00 – 18:30

PM Panel Discussion

18:30 – 19:30

Refreshments

20:00

*Gala Dinner & Group Photo*

SATURDAY 12TH NOVEMBER 2016

07:00 – 08:30

Group Breakfast

MYC AND INTEGRINS AS THERAPEUTIC TARGETS
Session Chair: Lluis Fajas 

08:30 – 09:00

Juha Klefstrom
University of Helsinki

REACTIVATING MYC APOPTOSIS PATHWAY IN BREAST CANCER

 

09:00 – 09:30

Jai Prakash
University of Twente

INTEGRIN ALPHA5: A KEY PROGNOSTIC AND THERAPEUTIC TARGET IN PANCREATIC TUMOR STROMA

09:30 – 09:45

Maria Rosaria Ambrosio
University of Naples

GLUCOSE IMPAIRS TAMOXIFEN RESPONSIVENESS MODULATING CTGF (Connective Tissue Growth Factor) IN BREAST CANCER CELLS

09:45 – 10:00

Vadim Pokrovsky
People's friendship University

ANTICANCER ACTIVITY OF L-LYSINE ALPHA-OXIDASE FROM TRICHODERMA CF. AUREOVIRIDE RIFAI

10:00 – 10:30

AM Panel Discussion

10:30 – 10:45

Closing Comments

10:45 – 11:45

Refreshments

Speakers

Invited Speakers

  • Prof. Lluis Fajas
    Director Department Physiology, UNIL
  • Prof. Adrian Harris
    Professor of Medical Oncology, University of Oxford
  • Prof. Arne Östman
    Professor, Karolinska Institutet
  • Prof. Isaac Witz
    Prof. Lab Chief, Tel Aviv University
  • Dr. Jacques Pouyssegur
    CNRS Research Director, University of Nice
  • Prof. Dr. Pierre Sonveaux
    Prof., Université catholique de Louvain (UCL)
  • Dr. Ubaldo Martinez Outschoorn
    Assistant Professor, Thomas Jefferson University
  • Dr. Myriam Fabre
    R&D Director, Oncomatryx Biopharma, S.L.
  • Dr. Michelangelo Campanella
    Reader in Pharmacology and Unit Head, The Royal Veterinary College, University of London and UCL Consortium for Mitochondrial Research
  • Assist. Prof. Ana Urbano
    Assistant Professor, University of Coimbra
  • Dr. Balázs Győrffy
    Assistant professor, MTA TTK
  • Dr. Mark Musters
    Project leader / Scientist, Lead Pharma
  • Dr. Balamurugan Kuppusamy
    Staff Scientist, National Cancer Institute/National Institutes of Health
  • Dr. Matthew Hirschey
    Assoc. Professor, Duke University

Feedback

Sign In

Your feedback has been received.